within Pharmacolibrary.Drugs.ATC.J;

model J04AB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 3.833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cycloserine is an antibiotic primarily used for the treatment of tuberculosis, particularly for multidrug-resistant Mycobacterium tuberculosis. It is a broad-spectrum antibiotic and acts by inhibiting cell wall synthesis. It is still used today as a second-line treatment option in cases where first-line drugs are ineffective or contraindicated.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult healthy volunteers after oral administration.</p><h4>References</h4><ol><li><p>Court, R, et al., &amp; McIlleron, H (2018). Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. <i>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</i> 22(1) 30–33. DOI:<a href=\"https://doi.org/10.5588/ijtld.17.0475\">10.5588/ijtld.17.0475</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29297422/\">https://pubmed.ncbi.nlm.nih.gov/29297422</a></p></li><li><p>Zhu, M, et al., &amp; Peloquin, CA (2001). Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. <i>Pharmacotherapy</i> 21(8) 891–897. DOI:<a href=\"https://doi.org/10.1592/phco.21.11.891.34524\">10.1592/phco.21.11.891.34524</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11718495/\">https://pubmed.ncbi.nlm.nih.gov/11718495</a></p></li><li><p>Zhou, H, et al., &amp; Wu, L (2015). Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study. <i>Clinical therapeutics</i> 37(6) 1292–1300. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2015.03.015\">10.1016/j.clinthera.2015.03.015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25869627/\">https://pubmed.ncbi.nlm.nih.gov/25869627</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AB01;
